Company Overview
| Stock Name | 上海君實生物醫藥科技股份有限公司 - B - Ｈ股 |
|---|---|
| Stock Code | 01877 |
| Company Full Name | 上海君實生物醫藥科技股份有限公司 - B - Ｈ股 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事生物制藥業務。 |
| Listing Date | 2018-12-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市自由貿易試驗區蔡倫路987號4層 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.junshipharma.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 19.38 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 61.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 307,986,960 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 23.75 |
|---|---|
| First Day Open | HK$ 23.5 |
| First Day Change | 22.55% |
| First Day Volume | 18500500.0 |
| First Day Turnover | 431273000.0 |
Use of Proceeds
| Use of Proceeds | 1、約40%或1177.60百萬港元的所得款項凈額將用于研發及商業化核心產品JS001，為JS001的臨床試驗提供資金； 2、約16%或471.04百萬港元的所得款項凈額將用于研發其他在研藥品，為臨床試驗提供資金； 3、約9%或264.96百萬港元的所得款項凈額將用于興建臨港生產基地及吳江生產基地； 4、約25%或736.00百萬港元的所得款項凈額將用于投資及收購制藥行業的公司，特別是具有與本公司互補的強大研發及/或商業化能力的公司； 5、約10%或294.40百萬港元的所得款項凈額將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (4)
中国国际金融香港证券有限公司 CE AEN894
花旗环球金融亚洲有限公司 CE AAA137
Credit Suisse (Hong Kong) Limited CE AAO017
复星国际证券有限公司 CE AAF432
Joint Bookrunners (6)
中国国际金融香港证券有限公司 CE AEN894
花旗环球金融亚洲有限公司 CE AAA137
Credit Suisse (Hong Kong) Limited CE AAO017
复星国际证券有限公司 CE AAF432
中信建投（国际）融资有限公司 CE BAU112
财通国际证券有限公司 CE AZF063
Joint Lead Managers (6)
中国国际金融香港证券有限公司 CE AEN894
花旗环球金融亚洲有限公司 CE AAA137
Credit Suisse (Hong Kong) Limited CE AAO017
复星国际证券有限公司 CE AAF432
中信建投（国际）融资有限公司 CE BAU112
财通国际证券有限公司 CE AZF063
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Highbury Investment Pte Ltd | 352,522,200 HKD | — | 11.45% | — | 6 months | 2019-06-24 |
| 2 | Loyal Valley Capital Advantage Fund LP | 720,722,820 HKD | — | 23.40% | — | 6 months | 2019-06-24 |
| 3 | Megastar Investment Management Limited | 117,500,940 HKD | — | 3.82% | — | 6 months | 2019-06-24 |
| 4 | TR Capital III, L.P. | 23,488,560 HKD | — | 0.76% | — | 6 months | 2019-06-24 |
| 5 | 北京鼎联鑫科技发展有限公司 | 164,516,820 HKD | — | 5.34% | — | 6 months | 2019-06-24 |
| 6 | 王树君 | 258,509,820 HKD | — | 8.39% | — | 6 months | 2019-06-24 |
| 7 | 俞建午 | 258,509,820 HKD | — | 8.39% | — | 6 months | 2019-06-24 |
Directors & Management
| Chairman | 熊俊 |
|---|---|
| Company Secretary | 王征宇 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 熊俊(8.93%);林利軍(12.72%) |
|---|
